BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Contreras E, de la Rubia J, Del Río-Garma J, Díaz-Ricart M, García-Gala JM, Lozano M; Grupo Español de Aféresis. [Diagnostic and therapeutic guidelines of thrombotic microangiopathies of the Spanish Apheresis Group]. Med Clin (Barc) 2015;144:331.e1-331.e13. [PMID: 25433791 DOI: 10.1016/j.medcli.2014.09.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Pérez-Cruz FG, Villa-Díaz P, Pintado-Delgado MC, Fernández_Rodríguez ML, Blasco-Martínez A, Pérez-Fernández M. Hemolytic uremic syndrome in adults: A case report. World J Crit Care Med 2017; 6(2): 135-139 [PMID: 28529915 DOI: 10.5492/wjccm.v6.i2.135] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Romero S, Sempere A, Gómez-seguí I, Román E, Moret A, Jannone R, Moreno I, Mendizábal S, Espí J, Peris A, Carbonell R, Cervera J, Pemán J, Bonanad S, de la Rubia J, Jarque I. Guía práctica de tratamiento urgente de la microangiopatía trombótica. Medicina Clínica 2018;151:123.e1-9. [DOI: 10.1016/j.medcli.2018.01.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gómez-Seguí I, Fernández-Zarzoso M, de la Rubia J. A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura. Expert Rev Hematol 2020;13:1153-64. [PMID: 32876503 DOI: 10.1080/17474086.2020.1819230] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Matute Guerrero A, Ocabo Buil P, Montes Aranguren M. Microangiopatía trombótica inducida por rifampicina. Medicina Clínica 2022. [DOI: 10.1016/j.medcli.2022.07.005] [Reference Citation Analysis]
5 Hernández Lorente E, Lluch García R, Monteagudo Santolaya E. Effectiveness of bortezomib in the treatment of thrombotic thrombocytopenic purpura: Case report. Med Clin (Barc) 2019;152:244-5. [PMID: 30139589 DOI: 10.1016/j.medcli.2018.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
6 Palanques-Pastor T, Megías-Vericat JE, Bosó Ribelles V, Gómez Seguí I, Poveda Andrés JL. Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment. Acta Haematol 2022;145:72-7. [PMID: 34352748 DOI: 10.1159/000517813] [Reference Citation Analysis]